Abstract
Since early 2020, over 123 million people worldwide have been diagnosed with coronavirus disease (Covid-19), but the true number of infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is undoubtedly higher. The seroprevalence of antibodies against SARS-CoV-2 can provide crucial epidemiological information about the extent of infections independent of virologically detected case numbers. There is no large population-based SARS-CoV-2 seroprevalence survey from Norway; thus we estimated SARS-CoV-2 seroprevalence in Norway before the introduction of vaccines and described its distribution across demographic groups. In November-December 2020, a total of 110,000 people aged 16 years or older were randomly selected from the National Population Register and invited to complete a questionnaire and provide a dried blood spot (DBS) sample. The response rate was 30%; compliance rate for return of DBS samples was 88%. The national weighted and adjusted seroprevalence was 0.9% (confidence interval 0.7-1.0).
Seroprevalence was highest among those aged 16-19 years (1.9%, 0.9-2.9), those born outside the Nordic countries 1.4% (1.0-1.9), and in the counties of Oslo 1.7 % (1.2-2.2) and Vestland 1.4% (0.9-1.8). The ratio of SARS-CoV-2 seroprevalence (0.9) to the cumulative incidence of virologically detected cases by mid-December 2020 (0.8%) was slightly above one. SARS-CoV-2 seroprevalence was low before the introduction of vaccines in Norway and was comparable to virologically detected cases, indicating that most cases in the first 10 months of the pandemic were detected. Preventive measures including contact tracing have been effective, people are complying with social distancing recommendations, and local efforts to contain outbreaks have been essential.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The project was funded from the Norwegian Research Council (project number 312730) and UiT The Arctic University of Norway.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the Regional Committee for Medical Research Ethics, North Norway (reference number: 154985/2020) and the Norwegian Data Protection Authority (reference number: 758042/2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* First authors
↵# Last author
erik.anda{at}uit.no, tonje.braaten{at}uit.no, kristin.benjaminsen.borch{at}uit.no, therese.h.nost{at}uit.no, sairah.chen{at}uit.no, marko.lukic{at}uit.no, eiliv.lund{at}uit.no, frode.forland{at}fhi.no, david.leon{at}lshtm.ac.uk, brita.askeland.winje{at}fhi.no, anne-martebakken.kran{at}fhi.no, mette.kalager{at}medisin.uio.no, fridtjol{at}gmail.com, torkjel.sandanger{at}uit.no
Data Availability
The datasets analysed during the current study are not publicly available due to local and national ethical and security policies, but can be obtained upon request from the corresponding author in an anonymized format after the study has been published.
